JP2025501746A - ウイルス感染症の治療における使用のための酵母から産生されたアルファ-1アンチトリプシン - Google Patents

ウイルス感染症の治療における使用のための酵母から産生されたアルファ-1アンチトリプシン Download PDF

Info

Publication number
JP2025501746A
JP2025501746A JP2024537865A JP2024537865A JP2025501746A JP 2025501746 A JP2025501746 A JP 2025501746A JP 2024537865 A JP2024537865 A JP 2024537865A JP 2024537865 A JP2024537865 A JP 2024537865A JP 2025501746 A JP2025501746 A JP 2025501746A
Authority
JP
Japan
Prior art keywords
aat
fragment
recombinant
protein
yeast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024537865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501746A5 (enExample
Inventor
シュタングル,マンフレッド
Original Assignee
アーテック メディカル ジーエムビーエイチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーテック メディカル ジーエムビーエイチ filed Critical アーテック メディカル ジーエムビーエイチ
Publication of JP2025501746A publication Critical patent/JP2025501746A/ja
Publication of JP2025501746A5 publication Critical patent/JP2025501746A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/84—Pichia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
JP2024537865A 2021-12-22 2022-12-22 ウイルス感染症の治療における使用のための酵母から産生されたアルファ-1アンチトリプシン Pending JP2025501746A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21216836 2021-12-22
EP21216836.3 2021-12-22
EP22166483.2 2022-04-04
EP22166483 2022-04-04
PCT/EP2022/087461 WO2023118424A1 (en) 2021-12-22 2022-12-22 Alpha-1 antitrypsin produced from yeast for use in the treatment of viral infections

Publications (2)

Publication Number Publication Date
JP2025501746A true JP2025501746A (ja) 2025-01-23
JP2025501746A5 JP2025501746A5 (enExample) 2025-12-08

Family

ID=84980906

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024537865A Pending JP2025501746A (ja) 2021-12-22 2022-12-22 ウイルス感染症の治療における使用のための酵母から産生されたアルファ-1アンチトリプシン

Country Status (8)

Country Link
US (1) US20250057927A1 (enExample)
EP (1) EP4453233A1 (enExample)
JP (1) JP2025501746A (enExample)
AU (1) AU2022422304A1 (enExample)
CA (1) CA3241852A1 (enExample)
IL (1) IL313247A (enExample)
TW (1) TW202334430A (enExample)
WO (1) WO2023118424A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4731251A1 (en) * 2023-06-22 2026-04-29 AATEC Medical GmbH Recombinant aat from yeast to treat bacterial respiratory infections
EP4730999A1 (en) * 2023-06-22 2026-04-29 AATEC Medical GmbH Recombinant aat from yeast to treat transplants
EP4480960A1 (en) * 2023-06-22 2024-12-25 AATEC Medical GmbH A recombinant human alpha-1 antitrypsin glycoprotein
JP2026525823A (ja) * 2023-06-22 2026-08-04 エイエイテック メディカル ゲーエムベーハー 組換えヒトアルファ-1アンチトリプシン糖タンパク質

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713249A (en) 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
US5266333A (en) 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
WO2021191900A1 (en) 2020-03-26 2021-09-30 Kamada Ltd. Methods for treating infectious diseases caused by coronavirus

Also Published As

Publication number Publication date
CA3241852A1 (en) 2023-06-29
IL313247A (en) 2024-08-01
AU2022422304A1 (en) 2024-06-20
TW202334430A (zh) 2023-09-01
WO2023118424A1 (en) 2023-06-29
US20250057927A1 (en) 2025-02-20
EP4453233A1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
US20250057927A1 (en) Alpha-1 antitrypsin produced from yeast for use in the treatment of viral infections
US20230414730A1 (en) A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
EP3325618B1 (en) Novel trypsin isoforms and their use
JP6030201B2 (ja) α‐1プロテイナーゼインヒビターのための組成物、方法およびキット
JP2023527791A (ja) ウイルス性呼吸器感染症を治療するための方法
CN101333258A (zh) 一种具有抗菌及促伤口愈合功能的融合多肽
EP3995130A1 (en) A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
KR102750010B1 (ko) 호흡기 바이러스 감염의 치료 또는 예방을 위한 수퍼옥시드 디스무타아제 활성을 갖는 폴리펩티드 및 세포외 소포체의 용도
CA2792727C (en) Therapy for influenza like illness
CN118434880A (zh) 由酵母生产的α-1抗胰蛋白酶用于治疗病毒感染的用途
WO2021164576A1 (zh) 用于抗冠状病毒感染的药物及其应用
KR20260030111A (ko) 재조합 인간 알파-1 항트립신 당단백질
EP4480960A1 (en) A recombinant human alpha-1 antitrypsin glycoprotein
EP4480493A1 (en) A recombinant human alpha-1 antitrypsin glycoprotein for treating non-viral inflammatory diseases of the lung
KR20080071116A (ko) 기도에 영향을 미치는 염증 질환에 있어서 활성화 단백질c의 기도 투여법
WO2024261179A1 (en) Recombinant aat from yeast to treat bacterial respiratory infections
AU2022380713A1 (en) Das181 variant compositions
JP2008308438A (ja) 新規なインフルエンザ治療および/または予防薬
CN121653105A (zh) 中性粒细胞弹性蛋白酶的融合蛋白及其制备方法与应用
WO2022207918A1 (en) COVID-19 Therapy
KIDO et al. Influenza Virus, Sendai Virus, and HIV
WO2004096852A1 (fr) Interferon$g(v) humain recombinant, son procede d'expression et ses utilisations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251127